Biomarkers & Diagnostics for Complex & Rare Diseases Summit

Biomarkers & Diagnostics (BM&Dx) for Complex & Rare Diseases Summit is organized by Hanson Wade and will be held from Jun 19 - 20, 2019 at The Westin Boston Waterfront, Boston, Massachusetts, United States of America.

Description:
The inaugural Biomarkers & Diagnostics for Complex & Rare Diseases Summit will unite leading pharma, biotech, Dx and healthcare organizations to advance the application of precision medicine for a range of diseases, including examples from; neurology, cardiovascular, renal, metabolic, dermatology, NASH, and rare diseases.

Tackling critical challenges in the discovery, translation, development, and commercialization of biomarker-driven and Dx-enabled therapeutics, this meeting will draw on the transferable learnings from a multitude of disease areas to improve treatment decision making and push the boundaries of the standard of care for patients.

Why This Is The Event For You?
The precision medicine industry is bigger than oncology. As diseases such as CVD and Alzheimer’s become the biggest healthcare burdens, the application of the precision medicine paradigm is now being heralded as the ticket to improving their complex therapeutic landscapes. The inaugural Biomarkers & Diagnostics for Complex & Rare Diseases Summit will focus on discovery, translational, clinical and commercial barriers to advancing the application of biomarker-driven and Dx-enabled therapeutics in a range of complex and rare diseases.
Key topics of discussion include…
• Accurate biomarker identification for patient selection and stratification
• Addressing the unmet clinical need of clinicians and patients
• Effective reimbursement and market access strategies
• Diagnostics and technologies for smaller, focused markets
• Regulatory pathways and requirements for treatments and tests
Built for discovery, translational, biomarker and diagnostic leaders throughout the industry, the meeting will tackle the gap in biomarker development and translational approaches and pave the path for the successful development of Dx-enabled precision medicines in complex and rare disease areas.

Speakers: Franziska Moeckel (Inova Health System), George Bashirians (Pfizer), Kenneth Rhodes (Yumanity Therapeutics), Naomi Aronson (Blue Cross Blue Shield Association), Gabriel Cohn (AvroBio), Michael Hutton (Eli Lilly And Co.)

Time: 8:00 am to 5:00 pm